Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes

Current Medical Research and Opinion

Volumn 20, Issue 4, 2004, Pages 541-553

  Tanenberg, Robert J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Diabetes; Insulin; Intensive therapy; Oral antidiabetic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; DIET; DOSE CALCULATION; DRUG FORMULATION; EDEMA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; METABOLIC SYNDROME X; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETINOPATHY; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 1942534577     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125003134     Document Type: Review

References (79)

1. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
2. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108(Suppl 6a):15S-22S
3. Campbell RK, White JR Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002;42:602-11
4. Scheen AJ. Clinical study of the month: Toxicity of hyperglycemia in intensive care and beneficial effects of optimized insulin therapy. Rev Med Liege 2001;56:859-861
5. Park S and Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19:124-30
6. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003;25(Suppl B):B32-46
7. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-6
8. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th ed. Philadelphia, PA: W.B. Saunders Co.; 2001. p. 821-35
9. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68
10. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70
11. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs 1999;58(Suppl 1): 7-10; discussion 75-82
12. Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther 1998;20:216-31; discussion 215
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539
14. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143
15. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 2004;27(Suppl 1):S1-S150
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356
17. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709
18. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-13
19. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30
20. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-38
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
23. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
24. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8
25. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörä lä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-84
26. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45-50
27. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 2003;26(Suppl 1):S1-S156
28. American College of Endocrinology, American Association of Clinical Endocrinologists. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(Suppl 1):5-11
29. American Association of Clinical Endocrinologists, American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract 2002;8(Suppl 1):41-82
30. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002;25(Suppl 1):S1-S147
31. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8
32. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A metaanalysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259-64
33. Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med 2003; May (Spec No.):63-72
34. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001;63:1747-56
35. Davis SN. Advances in oral therapy for type 2 diabetes. Postgrad Med 2000; May (Spec No.):16-20
36. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-22
37. Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607-15
38. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-72
39. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008-10
40. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78:1088-91
41. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest 1994;24(Suppl 3):3-10
42. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80
43. American Diabetes Association. Insulins: chart depicting the different types of insulin. Available from http://www.diabetes.org/community/forecast/ResourceGuide2003/ 2003ResourceGuide_P DF/Insulin.pdf. [Accessed 25 November 2003]
44. American Diabetes Association. Insulin administration. Diabetes Care 2002;25:S112-S115
45. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 1997;26:575-98
46. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997;337:176-83
47. Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51
48. Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998;82:689-719
49. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002;41:1043-57
50. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403
51. Rosenstock J, Schwartz SL, Clark Jr. CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
52. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9
53. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67
54. Riddle MC, Schneider J for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052-7
55. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32
56. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S for the Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7
57. American Association of Diabetes Educators. National standards for diabetes self-management education. Available from www.aadenet.org/AboutAADE/about_frame.html. [Accessed 18 November 2002]
58. Murray DP, Keenan P, Gayer E, et al. A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med 1988;5:750-4
59. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994;17:874-8
60. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
61. Holman RR, Turner RC. The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocrinol (Oxf) 1981;14:279-86
62. Edelman SV, Henry RR. Insulin therapy. Diagnosis and management of type 2 diabetes. 5th ed. Caddo, Oklahoma: Professional Communications, Inc.; 2002. p. 121-48
63. Ahmann AJ, Riddle MC. Insulin therapy in type 2 diabetes mellitus. In: Leahy JL, Cefalu WT, editors. Insulin therapy. New York (NY): Marcel Dekker, Inc.; 2002. p. 113-25
64. Riddle MC, Rosenstock J, Gerich J on behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
65. Fritsche A, Schweitzer MA, Häring H-U and the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003;138:952-9
66. Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Ann Med 1996;28:439-44
67. Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
68. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8
69. Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. Available from http://www.tdh.state.tx.us/diabetes/pdf/algorithms/inst2.pdf. [Accessed 4 November 2003]
70. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care 1998;21:87-92
71. DeFronzo RA, Goodman AM for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9
72. Hermann LS, Scherstén B, Bitzén P-O, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9
73. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35
74. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW for the Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998;21:1462-9
75. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-7
76. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24
77. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
78. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5
79. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211-7